Anti-ErbB3 [RTJ1]

Cat. #151157

Anti-ErbB3 [RTJ1]

Cat. #: 151157

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: ErbB3 (Her3)

Class: Monoclonal

Application: IHC ; IP ; WB

Reactivity: Human

Host: Mouse


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Inventor: Bill Gullick

Institute: Imperial Cancer Research Fund

Tool Details
Target Details

Tool Details


  • Name: Anti-ErbB3 [RTJ1]
  • Clone: RTJ1
  • Tool type ecom: Antibodies
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 105 kDa
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; IP ; WB
  • Description: Monoclonal antibody directed against ErbB3 kinase, widely prevalent in GI and breast tumours.
  • Immunogen: Synthetic Peptide from C terminus of human c-erbB3
  • Immunogen uniprot id: P21860
  • Isotype: IgM
  • Myeloma used: NS0

Target Details

  • Target: ErbB3 (Her3)
  • Molecular weight: 105 kDa
  • Target background: The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). c-erbB3 is normally found in non-dividing differentiated epithelial cells, neurones and hepatocytes. ErbB3 was found to be kinase impaired, having only 1/1000 the autophosphorylation activity of EGFR and no ability to phosphorylate other proteins. Therefore, ErbB3 must act as an allosteric activator. The kinase-impaired ErbB3 is known to form active heterodimers with other members of the ErbB family, most notably the ligand binding-impaired ErbB2. It has approximately 80% prevalence in a wide variety of tumours of the gastro-intestinal tract, and approximately 20% prevalence in breast cancer. This antibody is specific against c-erbB-3 oncoprotein that is expressed in a variety of human normal, foetal and neoplastic epithelial tissues.


  • Application: IHC ; IP ; WB


  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
  • Shipping conditions: Shipping at 4° C


  • Li et al. 2017. Oncotarget. 8(40):67140-67151. PMID: 28978022.
  • Lattanzio et al. 2016. Oncol Lett. 12(1):453-458. PMID: 27347164.
  • Anagnostou et al. 2010. Cancer Epidemiol Biomarkers Prev. 19(4):982-91. PMID: 20332259.
  • Analytic variability in immunohistochemistry biomarker studies.
  • Kapitanovic et al. 2000. J Cancer Res Clin Oncol. 126(4):205-11. PMID: 10782893.
  • Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival.
  • Naidu et al. 1998. Br J Cancer. 78(10):1385-90. PMID: 9823984.
  • Expression of c-erbB3 protein in primary breast carcinomas.
  • Srinivasan et al. 1998. J Pathol. 185(3):236-45. PMID: 9771476.
  • Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types.
  • Rajkumar et al. 1996. Clin Mol Pathol. 49(4):M199-202. PMID: 16696074.
  • c-erbB3 protein expression in ovarian cancer.
  • Rajkumar et al. 1993. J Pathol. 170(3):271-8. PMID: 8133400.
  • Expression of the c-erbB-3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1.